With that understanding, let's examine Qnexa, which as most obesity drug stock watchers know, combines two currently marketed medicines -- topiramate and phentermine -- into a single, weight-loss pill. Topiramate is an anticonvulsant. At higher doses than what's in Qnexa, topiramate is used to treat epileptic seizures and prevent migraine headaches.
After a recent meeting with FDA, Vivus disclosed that regulators are interested in seeing more safety data that could better define the incidence of birth defects, particularly cleft lips, in the babies born from women treated with topiramate. FDA's request for new safety data could delay Vivus' efforts to resubmit Qnexa for approval again after last fall's rejection.
Epilepsy and to a lesser extent migraine headaches are serious, acute conditions that affect a relatively smaller number of patients. Obesity is a chronic and non-fatal disease (at least directly) that affects millions of people, if not tens of millions of people. An obesity drug, if approved, could be very widely used. Women, most of childbearing age, will be particularly interested in obesity drugs.
That's the most likely reason for FDA's interest and concern about the topiramate component of Qnexa, even at lower doses. A teeny tiny risk of birth defects tied to topiramate use in a small number of epilepsy patients is acceptable; but the risk could become very much magnified if millions of obese women who may become pregnant start taking Qnexa.
Mike J. asks, "Follow you regularly, I appreciate your work. Did the Ariad Pharmaceuticals (ARIA) move surprise you? I was thinking ponatinib would be more the future driver of this stock." Ariad shares 34% to $7.32 intraday on Jan. 28 following the release of positive results from the phase III study of ridaforolimus ('rida) in sarcoma. The stock has since settled back to around $6.76 as I write this column Thursday. Aria was a $2 stock in early 2010. Mike is correct in that a lot of investors are looking past 'rida and focusing more on ponatinib. 'Rida's clinical development and most of the drug's economics are controlled by Merck (MRK). The Mtor inhibitor class of cancer drugs to which 'rida belongs is competitive and the 'rida data in sarcoma -- while meeting the primary endpoint with statistical significance -- are not without concerns. [A three-week improvement in median progression-free survival favoring 'rida compared to placebo looks rather anemic even though the relative reduction in the risk of progression was a more robust 28%.] Data is forthcoming on a potential survival benefit, if any, from the study, which while not necessarily required for approval, certainly can't hurt.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV